Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2]. |
In vivo | Ormutivimab, at a single dose of 20 IU/kg administered via intramuscular injection, conferred protection to beagles against the lethal challenge of RABV BD06. Similarly, a single intramuscular injection of Ormutivimab, at dosages of 20 IU/kg and 100 IU/kg, provided protective immunity to Kunming mice subjected to various rabies virus strains. |
Synonyms | rhRIG, NM57 |
Molecular Weight | N/A |
CAS No. | 2449086-91-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ormutivimab 2449086-91-1 rhRIG NM57 inhibitor inhibit